Sat, Aug 30, 2014, 6:12 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Nymox Pharmaceutical Corporation Message Board

  • brewvestor brewvestor Apr 27, 2011 10:08 PM Flag

    NEWMOX & Jailer116

    I posted the below on another board and I thought you guys might be able to help as well. I'm just getting into this company so I have a lot of questions.

    From a financial standpoint it looks ok for a biotech. No debt. $13MM in cash with access to $12MM more with no real dilution. Does anyone know anything about this Lorrow-Greyse fund? I can't find anything on them.

    There is a lot of competition in the prostate shrinking market, but I think doctors will like the delivery of NX-1207. Wouldn't a doctor prefer to give a once-a-year shot in their office that prescribing another drug? They get the revenue for the procedure. Also, as a patient I would rather not take a daily drug that flows through the entire system when this can be injected directly.

    Nymox's other products at this stage seem to be too small (test strips) or too far off (all their other development programs).

    Adam Feuerstein seems to think the trials of NX-1207 are schrouded in mystery. I don't usually put a lot of weight on his negative opinons (b/c he is a known contrarian), but he does have a point. Why has the company not released more long term data about the phase 2 trials or any real guidance about the current phase 3 trials?

    What is everyone's opinion about the endpoints in these two trials?

    Clinicaltrials.gov says the trials will be completed in May 2012. Is this accurate? If so, doesn't that mean NDA not likely until 2013?

    Also, does anyone have a copy of the analyst reports released (Singular or BioLogic)? I've contacted the company, but they haven't sent me anything.

    I know that is a lot of questions, but any help would be greatly appreciated. Thanks.

    Brew

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
NYMX
5.06+0.11(+2.22%)Aug 29 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.